Enanta Pharmaceuticals (NASDAQ: ENTA) reported fiscal Q3 2026 revenue of $14.4 million, down 21.6% from $18.3 million a year earlier, while diluted loss per share narrowed to $0.67 from $0.85. Net loss nevertheless widened to $19.5 million as higher royalty-related interest expense offset lower research and administrative costs. Cash and marketable securities totaled $211.5 million, with management projecting funding into fiscal 2029.

Core financial results

Quarterly revenue consisted entirely of royalties from AbbVie’s MAVYRET/MAVIRET hepatitis C regimen. The decline reflected lower HCV sales reported by AbbVie compared with the prior-year period.

Operating expenses fell 15.1%, led by lower clinical trial spending for Enanta’s RSV programs. Increased immunology program costs provided a partial offset, while lower stock-based compensation reduced general and administrative expenses.

Lower operating costs were offset by royalty-related interest expense

The quarter produced opposing trends at the operating and net-income levels. The $5.6 million reduction in operating expenses more than offset the $4.0 million revenue decline, allowing the operating loss to narrow by approximately $1.7 million.

Below the operating line, interest expense increased by $2.5 million and interest and investment income declined by $0.4 million. Those changes more than erased the operating improvement, causing the net loss to widen by approximately $1.2 million.

The higher interest expense relates to Enanta’s sale of a portion of its future AbbVie royalties to OMERS. Enanta recognizes 100% of the earned royalties as revenue, but 54.5% of the related cash payments goes to OMERS through June 30, 2032, subject to the transaction cap. The original $200 million upfront payment is recorded as a liability, and the associated interest expense changes with forecast royalty revenue. Enanta attributed the latest increase in interest expense to a higher forecast for future AbbVie royalty revenue, even though current-quarter royalty revenue declined.

Diluted loss per share improved despite the wider net loss because weighted-average diluted shares increased to 29.1 million from 21.4 million, an increase of approximately 36%. The per-share improvement therefore does not indicate an improvement in bottom-line profitability.

Pipeline progress and upcoming milestones

Clinical development remains the primary operating focus. Enanta began dosing pediatric patients in LOTUS and plans to move zelicapavir into a registrational trial for high-risk adults, while its immunology portfolio has several milestones scheduled for the second half of 2026.

The European Commission also approved AbbVie’s MAVIRET for acute HCV infection in adults and children aged three years and older. MAVIRET is the source of Enanta’s royalty revenue, although the company did not quantify the approval’s expected financial effect.

Liquidity and balance sheet

Cash, cash equivalents, and short- and long-term marketable securities totaled $211.5 million at June 30, 2026, up from $188.9 million at September 30, 2025. The June balance consisted of $33.4 million in cash and cash equivalents, $156.1 million in short-term securities, and $22.0 million in long-term securities.

The liability associated with the royalty sale totaled approximately $125.1 million, including current and long-term portions, compared with $141.8 million at the end of fiscal 2025. Management expects available liquidity and Enanta’s retained portion of future royalties to fund existing operations and development programs into fiscal 2029.

The provided release did not include a cash-flow statement, so quarterly operating cash use cannot be calculated from these results alone.

Recent insider transactions

The supplied insider summary recorded no insider purchases or sales during the most recent six-month period and listed total insider holdings of 1.36 million shares. The latest detailed entries included six zero-price stock awards in February 2026 and four officer sales in December 2025; the reported values for awards do not represent their potential economic value.

These records establish the transactions but do not, by themselves, indicate insiders’ views of Enanta’s outlook.

Risks investors need to watch

• Dependence on one royalty stream: Quarterly revenue came entirely from MAVYRET/MAVIRET, and lower AbbVie HCV sales reduced revenue by 21.6%.
• Royalty revenue does not fully translate into cash: Enanta recognizes all earned royalties as revenue but pays 54.5% of the related cash to OMERS under the royalty transaction.
• Clinical execution and data risk: Major value-driving milestones depend on starting RESOLVE on schedule and producing favorable data from zelicapavir and EDP-978 trials.
• Patent litigation uncertainty: Enanta petitioned for a rehearing after the Federal Circuit ruled claims in its U.S. patent invalid. A separate European Unified Patent Court hearing is scheduled for September 29, 2026.
• Runway assumptions depend on development spending and royalties: The fiscal 2029 liquidity outlook incorporates anticipated program costs and retained future royalties, both of which can change.

Summary

Enanta reduced operating expenses enough to narrow its operating loss despite lower HCV royalty revenue, but a sharp increase in royalty-related interest expense pushed the net loss higher. The company enters its upcoming clinical milestones with $211.5 million in cash and securities and a stated runway into fiscal 2029. Execution of the RESOLVE trial, EDP-978 Phase 1 results, and progress across the early immunology portfolio are the principal items to monitor next.

Find out more